- Home
- GRF vs ECOR Comparison
GRF vs ECOR Comparison
Compare GRF & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRF
- ECOR
- Stock Information
- Founded
- GRF 1989
- ECOR 2005
- Country
- GRF United States
- ECOR United States
- Employees
- GRF N/A
- ECOR N/A
- Industry
- GRF Finance/Investors Services
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- GRF Finance
- ECOR Health Care
- Exchange
- GRF Nasdaq
- ECOR Nasdaq
- Market Cap
- GRF 42.6M
- ECOR 40.0M
- IPO Year
- GRF N/A
- ECOR 2018
- Fundamental
- Price
- GRF $10.69
- ECOR $4.86
- Analyst Decision
- GRF
- ECOR Strong Buy
- Analyst Count
- GRF 0
- ECOR 2
- Target Price
- GRF N/A
- ECOR $25.50
- AVG Volume (30 Days)
- GRF 3.0K
- ECOR 44.3K
- Earning Date
- GRF 01-01-0001
- ECOR 11-05-2025
- Dividend Yield
- GRF 3.70%
- ECOR N/A
- EPS Growth
- GRF N/A
- ECOR N/A
- EPS
- GRF 1.16
- ECOR N/A
- Revenue
- GRF N/A
- ECOR $27,700,000.00
- Revenue This Year
- GRF N/A
- ECOR $23.74
- Revenue Next Year
- GRF N/A
- ECOR $42.02
- P/E Ratio
- GRF $8.15
- ECOR N/A
- Revenue Growth
- GRF N/A
- ECOR 30.16
- 52 Week Low
- GRF $7.93
- ECOR $4.16
- 52 Week High
- GRF $10.19
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- GRF 47.67
- ECOR 44.25
- Support Level
- GRF $10.55
- ECOR $4.71
- Resistance Level
- GRF $10.80
- ECOR $5.08
- Average True Range (ATR)
- GRF 0.25
- ECOR 0.25
- MACD
- GRF -0.02
- ECOR -0.00
- Stochastic Oscillator
- GRF 12.40
- ECOR 23.66
About GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.